shares Novo Nordisk The Danish pharmaceutical giant jumped on Friday after reporting positive early results for its once-weekly almond-based obesity drug.

Trials showed that the treatment, which is administered via injection, led to an average weight loss of 22% in obese and overweight patients.

Shares were up 9.2% at 11:22 a.m. London time.

Marzipan targets the same gut hormone as Wegovy Mimics (called GLP-1) as well as the pancreatic hormone that affects hunger. Wegovy is Novo Nordisk’s flagship obesity drug, while Ozempic is its diabetes treatment.

Nova said the biggest adverse effects reviewed for amygdala treatments were in the gastrointestinal tract, with the vast majority being “mild to moderate in severity.”

“We are very encouraged by the results of subcutaneous phase 1B/2A of the amygdala in patients who are overweight or obese,” Martin Lange, executive vice president of Novo Nordisk, said in a statement.

“The results seen in the trial support the gravimetric potential of this novel single-molecule GLP-1 and amyloid receptor agonist amygdalin, which we have previously seen in oral formulations.”

Novo is also developing an amygdala obesity drug early stage trials Announced in September, it resulted in an average weight loss of 13.1% after 12 weeks.

This is a developing story. Please check back for updates.